Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis. 

RSS icon
Video interview with ASNC President Lawrence Phillips, MD, NYU, who is encouraging the modernization of nuclear cardiology labs and expansion into new diagnostic areas.

ASNC president pushes to modernize nuclear cardiology, expand the specialty's reach

ASNC President Lawrence Phillips, MD, wants to see nuclear cardiologists modernize their labs and embrace new strategies for the evaluation of amyloidosis, sarcoidosis and inflammation.

Jamie Bourque, MD, medical director of the nuclear cardiology and stress laboratory, and medical director of the echocardiography lab, at the University of Virginia, discusses a new multimodality consensus statement for imaging cardiac amyloidosis. This area has rapidly expanded over the past couple years now that there are drugs to treat the condition.

New ASNC quality metrics will support standardization of imaging for cardiac amyloidosis

Interest in cardiac amyloidosis has been on the rise in recent years. Jamie Bourque, MD, talked to Cardiovascular Business about an upcoming consensus statement focused on using cardiac imaging to evaluate patients for signs of this serious condition. 

Rob deKemp, PhD, FASNC, University of Ottawa, Canada, explains new nuclear cardiac imaging dose lowering techniques for PET and SPECT.

How to achieve much lower radiation doses in cardiac nuclear imaging

The radiation doses associated with CT have decreased significantly, leaving nuclear cardiology as the modality with the highest doses in all of cardiac imaging. Rob deKemp, PhD, talked to us about some of the many ways imagers can work to address this issue.

Thumbnail

Pyrophosphate imaging agent shortage reported, could last weeks

Supply chain disruptions are blamed for the lack of production.

Jamie Bourque, MD, discusses fluorodeoxyglucose (FDG) and its growing use cases in cardiac PET imaging He discussed the radiotracer in sessions at ASNC 2023. #ASNC #ASNC23 #ASNC2023

The expanding scope of FDG-PET in nuclear cardiac imaging

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

Robert Hendel, MD, Tulane University and former ASNC president, explains the pressing business aspects of nuclear cardiology and why ASNC included business management sessions at its 2023 annual meeting. #ASNC #ASNC23 #ASNC2023

Business considerations in the modern nuclear cardiology practice

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Timothy Bateman, MD, co-director, cardiovascular radiologic imaging program, Saint Luke's Mid America Heart Institute, professor of medicine at the University of Missouri-Kansas City School of Medicine, and an ASNC past-president, is one of the authors on the AURORA study. He spoke with Cardiovascular Business about the study and what it is like to work with flurpiridaz.

Flurpiridaz will have a major impact on cardiac PET and nuclear imaging

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

Video of ASNC President Mouaz Al-Mallah, MD, explaining some long-COVID cardiac symptoms might be due to coronary microvascular dysfunction. He was part of a recent study that used PET top assess myocardial perfusion that found there is impaired microvascular flow in long-COVID patients.

PET imaging helps assess coronary microvascular dysfunction in long COVID patients

Researchers noted that patients appeared to have myocarditis at first, but a closer examination revealed it was something else entirely. 

Displaying 17 - 24 of 82

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.